Vanda Pharmaceuticals Inc Total Assets
Vanda Pharmaceuticals Inc total assets. Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) holds total assets worth $488.95 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Vanda Pharmaceuticals Inc (VNDA) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Vanda Pharmaceuticals Inc (2004–2025)
Total assets of Vanda Pharmaceuticals Inc from 2004 to 2025. This chart illustrates how Vanda Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See VNDA share price today for real-time trading data and today's change.
Vanda Pharmaceuticals Inc - Asset Composition Analysis
Vanda Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Vanda Pharmaceuticals Inc total assets breakdown as of December 2025. Vanda Pharmaceuticals Inc's total assets of $488.95 Million consist of 71.0% current assets and 29.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.4% |
| Accounts Receivable | $54.58 Million | 11.2% |
| Inventory | $1.85 Million | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $117.09 Million | 24.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Vanda Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Vanda Pharmaceuticals Inc (VNDA) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vanda Pharmaceuticals Inc's current assets represent 71.0% of total assets in 2025, a decrease from 92.7% in 2004.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2025, down from 91.6% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 24.0% of total assets.
Vanda Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Vanda Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Vanda Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 4.39 | 6.82 |
| Quick Ratio | 2.38 | 4.37 | 6.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $202.10 Million | $338.91 Million | $359.44 Million |
Vanda Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Vanda Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.10 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -25.5% |
| Total Assets | $488.95 Million |
| Market Capitalization | $229.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vanda Pharmaceuticals Inc's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vanda Pharmaceuticals Inc's assets decreased by 25.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual total assets of Vanda Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $488.95 Million | -25.49% |
| 2024-12-31 | $656.20 Million | +1.20% |
| 2023-12-31 | $648.44 Million | +2.24% |
| 2022-12-31 | $634.25 Million | +6.81% |
| 2021-12-31 | $593.79 Million | +11.31% |
| 2020-12-31 | $533.46 Million | +10.28% |
| 2019-12-31 | $483.75 Million | +45.65% |
| 2018-12-31 | $332.13 Million | +61.68% |
| 2017-12-31 | $205.43 Million | -2.35% |
| 2016-12-31 | $210.37 Million | -1.26% |
| 2015-12-31 | $213.05 Million | +24.08% |
| 2014-12-31 | $171.70 Million | +19.78% |
| 2013-12-31 | $143.35 Million | +5.83% |
| 2012-12-31 | $135.45 Million | -25.83% |
| 2011-12-31 | $182.62 Million | -14.30% |
| 2010-12-31 | $213.10 Million | -5.59% |
| 2009-12-31 | $225.71 Million | +352.03% |
| 2008-12-31 | $49.93 Million | -48.45% |
| 2007-12-31 | $96.86 Million | +167.13% |
| 2006-12-31 | $36.26 Million | +1.42% |
| 2005-12-31 | $35.75 Million | +101.40% |
| 2004-12-31 | $17.75 Million | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more